HOOK
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in Phase I/II clinical trial for the treatment of human papillomavirus 16-positive cancers. The company's preclinical stage products include HB-300 program for prostate cancer; and HB-700 for targeting mutated KRAS in pancreatic, colorectal, and lung cancer. HOOKIPA Pharma Inc. has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. The company was incorporated in 2011 and is headquartered in New York, New York.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q2 | -0.40 | $7M | -$7M |
| 2025 Q1 | -1.23 | $2M | $32,000 |
| 2024 Q4 | -1.99 | $1M | -$21M |
| 2024 Q3 | -1.10 | $5M | -$18M |
| 2024 Q2 | -1.52 | $1M | -$14M |
| 2024 Q1 | 1.15 | $37M | -$24M |
| 2023 Q4 | -2.20 | $7M | -$12M |
| 2023 Q3 | -1.73 | $7M | -$27M |